Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.
The company suspended operations in May 2010 and laid off its entire staff.
In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.
The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40% in the past year.
In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- The Martian: Blows Gravity and Interstellar out of the water
- Labour lurches to the extreme left over TPP
- MARKET CLOSE: Shares rise, led by A2 after $40m placement; Contact, Meridian, MRP gain
- Too soon to compare charter and state schools, says Seymour
- How John Key could split Labour, A tale of two funds, Why isn’t the NXT market working?